Last 34 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -8.30 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 724.75 | 281.75 | 6860.24 | 654.08 | 2162.49 | — | — | 2217.27 | 1321.82 | — | 1220.72 | 247.48 | 80.79 |
| — | — | — | -70.5% | +63.6% | — | — | +795.9% | +1536.1% | — | +111.8% | -55.6% | -3.4% | |
| P/B Ratio | 3.90 | 4.41 | 3.66 | 2.30 | 2.49 | 3.53 | 4.91 | 4.26 | 3.87 | 4.43 | 3.08 | 3.85 | 3.09 |
| — | +25.0% | -25.5% | -45.9% | -35.6% | -20.3% | +59.3% | +10.7% | +25.2% | +42.3% | +2.6% | +51.7% | -10.6% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Crinetics Pharmaceuticals, Inc.'s operating margin was -3440.6% in Q4 2025, up 96269.9 pp QoQ. The trailing four-quarter average of -36633.5% lags the current quarter, suggesting the recent improvement is above-trend.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 80.1% | 111.8% | 100.0% | 100.0% | 100.0% | — | — | 100.0% | 100.0% | — | 100.0% | 100.0% | 100.0% |
| — | — | — | 0.0% | 0.0% | — | — | 0.0% | 0.0% | — | 0.0% | 0.0% | 0.0% | |
| Operating Margin | -9534.5% | -3440.6% | -99710.5% | -12523.0% | -30860.1% | — | — | -20747.6% | -11488.9% | — | -17045.4% | -5363.9% | -1790.9% |
| — | — | — | +39.6% | -168.6% | — | — | -286.8% | -541.5% | — | -79.7% | +45.3% | -65.8% | |
| Net Margin | -8585.2% | -3161.3% | -90972.7% | -11216.0% | -26807.2% | — | — | -18560.2% | -10457.8% | — | -16606.4% | -5159.8% | -1716.9% |
| — | — | — | +39.6% | -156.3% | — | — | -259.7% | -509.1% | — | -81.4% | +46.5% | -55.2% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -40.2% | -11.9% | -11.6% | -9.5% | -7.5% | -7.5% | -9.2% | -8.7% | -9.5% | -11.1% | -14.3% | -19.1% | -15.4% |
| — | -59.3% | -25.6% | -9.8% | +20.7% | +32.5% | +35.6% | +54.5% | +38.6% | +17.9% | -26.1% | -55.1% | -41.4% | |
| ROA | -36.3% | -10.6% | -10.5% | -8.7% | -6.9% | -6.8% | -8.2% | -7.7% | -8.3% | -9.4% | -12.3% | -16.8% | -13.8% |
| — | -55.6% | -27.6% | -12.7% | +16.6% | +27.8% | +33.3% | +53.9% | +39.9% | +22.9% | -18.3% | -49.6% | -36.4% | |
| ROIC | -37.8% | -10.3% | -9.8% | -8.1% | -7.2% | -8.5% | -11.5% | -11.2% | -10.3% | -9.5% | -13.1% | -17.3% | -13.6% |
| — | -21.6% | +14.2% | +27.0% | +30.4% | +10.6% | +12.7% | +35.6% | +24.1% | +19.0% | -30.9% | -30.5% | +21.0% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 46.5% YoY to 12.32x, tightening the short-term liquidity position. Debt/Equity has risen for 5 consecutive quarters, indicating increasing financial leverage that investors should watch closely.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.05 | 0.05 | 0.05 | 0.04 | 0.04 | 0.04 | 0.06 | 0.06 | 0.06 | 0.10 | 0.10 | 0.01 | 0.01 |
| — | +25.3% | -27.3% | -33.6% | -32.5% | -59.3% | -33.8% | +535.8% | +496.1% | +887.0% | +907.5% | +52.0% | +8.1% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 12.32 | 12.32 | 15.12 | 17.80 | 22.53 | 23.04 | 16.38 | 16.09 | 17.72 | 13.07 | 14.23 | 8.73 | 11.60 |
| — | -46.5% | -7.7% | +10.6% | +27.1% | +76.4% | +15.1% | +84.2% | +52.7% | +4.9% | -7.6% | -45.2% | -28.4% | |
| Quick Ratio | 12.30 | 12.30 | 15.12 | 17.80 | 22.53 | 23.04 | 16.38 | 16.09 | 17.72 | 13.07 | 14.23 | 8.73 | 11.60 |
| — | -46.6% | -7.7% | +10.6% | +27.1% | +76.4% | +15.1% | +84.2% | +52.7% | +4.9% | -7.6% | -45.2% | -28.4% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 34 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonCrinetics Pharmaceuticals, Inc.'s current P/E is -8.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Crinetics Pharmaceuticals, Inc.'s current operating margin is -9534.5%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Crinetics Pharmaceuticals, Inc.'s business trajectory between earnings reports.